UnitedHealth vs. Johnson & Johnson: Which Stock Is the Better Buy After Q3 Earnings?
UnitedHealth (UNH) and Johnson & Johnson (JNJ) reported Q3 earnings, with UNH beating estimates and raising its full-year EPS outlook to $20.50. JNJ's earnings declined but revenue grew, with mixed performance across divisions. UNH trades at a lower forward P/E (19X) and offers a higher dividend yield (2.45%) than JNJ (23X, 2%). Analysts favor UNH for its earnings recovery and valuation.
How this was made
The 30-second read
Why it matters
UNH's stronger earnings and higher guidance suggest a bullish catalyst, while JNJ's mixed results may lead to a more cautious market response.
Market read
Both companies are large‑cap health‑care leaders; their earnings updates can move sector ETFs and influence investor allocation within health‑care.
What to watch
UNH's Medicare Advantage reimbursement pressures and Optum challenges could temper long‑term upside despite the earnings beat.
Background
The article compares Q3 earnings and outlooks of UnitedHealth Group and Johnson & Johnson, focusing on earnings, guidance, valuation, and dividend yields.
Ticker impact
UnitedHealth reported Q3 earnings beat and raised full-year EPS guidance to at least $20.50, above consensus.
likely upward pressure as market prices in stronger earnings and higher guidance
Beat EPS by 14% and raised guidance above expectations, indicating earnings momentum.
Johnson & Johnson posted Q3 earnings beat and lifted 2026 EPS guidance to $11.05‑$11.15, slightly below consensus.
potential modest pressure or sideways movement as guidance trails expectations
EPS beat is small and guidance is below consensus, offset by strong pharma performance.
Market effects
Both results influence the healthcare sector, with UNH's cost‑management success highlighting potential upside for insurers, while JNJ's mixed momentum may weigh on pharma/medtech peers.
U.S. market sentiment may improve for health‑care stocks after strong insurer earnings.
Large-cap health names can affect global health‑care ETFs and indices.
Counterpoint
Investors may view JNJ's guidance shortfall as a buying opportunity if the market overreacts to the modest miss.
Key entities
- companyUnitedHealth Group
Health insurer and services provider
- companyJohnson & Johnson
Diversified health‑care conglomerate
